Plasma urotensin II as a marker for severity of rheumatic valve disease

Tohoku Journal of Experimental Medicine

Volumn 218, Issue 1, 2009, Pages 57-62

  Ozer, Orhan ^a   Davutoglu, Vedat ^a   Ercan, Suleyman ^a   Akcay, Murat ^b   Sari, Ibrahim ^a   Sucu, Murat ^a   Celik, Ahmet ^a   Aksoy, Nur ^a   Cicek, Hulya ^a   Behcet, Al ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Ataturk Education and Training Hospital   (Turkey)

Author keywords

Echocardiography; Functional class; Pulmonary hypertension; Rheumatic valve disease; Urotensin

Indexed keywords

BIOLOGICAL MARKER; UROTENSIN II;

ADULT; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SIZE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; PROTEIN BLOOD LEVEL; RHEUMATIC HEART DISEASE; TRICUSPID VALVE REGURGITATION;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; RHEUMATIC HEART DISEASE; TRICUSPID VALVE INSUFFICIENCY; UROTENSINS;

EID: 69249147325     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.218.57     Document Type: Article

References (34)

1. Ames, R.S., Sarau, H.M., Chambers, J.K., Willette, R.N., Aiyar, N.V., Romanic, A.M., Louden, C.S., Foley, J.J., Sauermelch, C.F., Coatney, R.W., Ao, Z., Disa, J., Holmes, S.D., Stadel, J.M., Martin, J.D., Liu, W.S., Glover, G.I., Wilson, S., McNulty, D.E., Ellis, C.E., Elshourbagy, N.A., Shabon, U., Trill, J.J., Hay, D.W., Ohlstein, E.H., Bergsma, D.J. & Douglas, S.A. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR 14. Nature, 401, 282-286.
2. Cheitlin, M.D., Armstrong, W.F., Aurigemma, G.P., Beller, G.A., Bierman, F.Z., Davis, J.L., Douglas, P.S., Faxon, D.P., Gillam, L.D., Kimball, T.R., Kussmaul, W.G., Pearlman, A.S., Philbrick, J.T., Rakowski, H. & Thys, D.M. (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J. Am. Coll. Cardiol., 42, 954-970.
3. Cheung, B.M., Leung, R., Man, Y.B. & Wong, L.Y. (2004) Plasma concentration of urotensin II is raised in hypertension. J. Hypertens., 22, 1341-1344.
4. Davutoglu, V., Celik. A. & Aksoy, M. (2005a) Contribution of Selected Serum Inflammatory Mediators to the Progression of Chronic Rheumatic Valve Disease, Subsequent Valve Calcification and NYHA Functional Class. J. Heart Valve Dis., 14, 251-256.
5. Davutoglu, V., Celik, A., Aksoy, M., Sezen, Y., Soydinc, S. & Gunay, N. (2005b) Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease. Eur. J. Heart Fail., 7, 532-536.
6. Djordjevic, T., BelAiba, R.S., Bonello, S., Pfeilschifter, J., Hess, J. & Gorlach, A. (2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 25, 519-525.
7. Douglas, S.A., Tayara, L., Ohlstein, E.H., Halawa, N. & Giaid, A. (2002) Congestive heart failure and expression of myocardial urotensin II. Lancet, 359, 1990-1997.
8. Enriquez-Sarano, M., Bailey, K.R., Seward, J.B., Tajik, A.J., Krohn, M.J. & Mays, J.M. (1993) Quantitative Doppler assessment of valvular regurgitation. Circulation, 87, 841-848.
9. Hall, S.A., Brickner, M.E., Willett, D.L., Irani, W.N., Afridi, I. & Graybun, P.A. (1997) Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta. Circulation, 95, 636-642.
10. Haris, G.S., Lust, R.M. & Katwa, L.C. (2007) Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula. Peptides, 28, 1483-1489.
11. Heringlake, M., Kox, T., Uzun, O., Will, B., Bahlmann, L., Klaus, S., Eleftheriadis, S., Armbruster, F.P., Franz, N. & Kraatz, E. (2004) The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul. Pept., 121, 129-136.
12. Johns, D.G., Ao, Z., Naselsky, D., Herold, C.L., Maniscalco, K., Sarov-Blat, L., Steplewski, K., Aiyar, N. & Douglas, S.A. (2004) Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn. Schmiedebergs. Arch. Pharmacol., 370, 238-250.
13. Khan, S.Q., Bhandari, S.S., Quinn, P., Davies, J.E. & Ng, L.L. (2007) Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int. J. Cardiol., 117, 323-328.
14. Krüger, S., Graf, J., Kunz, D., Stickel, T., Merx, M.W., Hanrath, P. & Janssens, U. (2005) Urotensin II in patients with chronic heart failure. Eur. J. Heart Fail., 7, 475-478.
15. MacLean, M.R., Alexander, D., Stirrat, A., Gallagher, M., Douglas, S.A., Ohlstein, E.H., Morecroft, I. & Polland, K. (2000) Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol., 130, 201-204.
16. Mallamaci, F., Cutrupi, S., Pizzini, P., Tripepi, G. & Zoccali, C. (2005) Urotensin II in endstage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J. Nephrol., 18, 727-732.
17. Marcus, R.H., Sareli, P., Pocock, W.A. & Barlow, J.B. (1994) The Spectrum of Severe Rheumatic Mitral Valve Disease in a Developing Country: Correlations among Clinical Presentation, Surgical Pathologic Findings, and Hemodynamic Sequelae. Ann. Intern. Med., 120, 177-183.
18. Ng, L.L., Loke, I., O'Brien, R.J., Squire, I.B. & Davies, J.E. (2002) Plasma Urotensin in Human Systolic Heart Failure. Circulation, 106, 2877-2880.
19. Ong, K.L., Wong, L.Y. & Cheung, B.M. (2008) The role of urotensin II in the metabolic syndrome. Peptides, 29, 859-867.
20. Ozer, O., Davutoglu, V., Sari, I., Akkoyun, D.C. & Sucu, M. (2009) The Spectrum of Rheumatic Heart Disease in the Southeastern Anatolia Endemic Region: Results from 1,900 Patients. J. Heart Valve Dis., 18, 68-72.
21. Pakala, R. (2008) Role of urotensin II in atherosclerotic cardiovascular diseases. Cardiovasc. Revasc. Med., 9, 166-178.
22. Prosser, H.C., Forster, M.E., Richards, A.M. & Pemberton, C.J. (2008) Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. Peptides, 29, 770-777.
23. Richards, A.M., Nicholls, M.G., Lainchbury, J.G., Fisher, S. & Yandle, T.G. (2002) Plasma urotensin II in heart failure. Lancet, 360, 545-546.
24. Rizvi, S.F., Khan, M.A., Kundi, A., Marsh, D.R., Samad, A. & Pahsa, O. (2004) Status of rheumatic heart disease in rural Pakistan. Heart, 90, 394-399.
25. Russell, F.D., Meyers, D., Galbraith, A.J., Bett, N., Toth, I., Kearns, P. & Molenaar, P. (2003) Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol., 285, H1576-H1581.
26. Sari I. & Davutoglu, V. (2008) Association of chronic subclinical inflammation with severity and progression of rheumatic valve disease. Int. J. Cardiol., 124, 263.
27. Schiller, N.B., Shah, P.M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I., et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr., 2, 358-367.
28. Song, B.G., Jeon, E.S., Kim, Y.H., Kang, M.K., Doh, J.H., Kim, P.H., Ahn, S.J., Oh, H.L., Kim, H.J., Sung, J.D., Lee, S.C., Gwon, H.C., Kim, J.S., Kim, D.K., Lee, S.H., Hong, K.P., Park, J.E., Lee, S.Y. & Lee, J.K. (2005) Correlation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failure. Korean J. Intern. Med., 20, 26-32.
29. Suguro, T., Watanabe, T., Ban, Y., Kodate, S., Misaki, A., Hirano, T., Miyazaki, A. & Adachi, M. (2007) Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am. J. Hypertens., 20, 211-217.
30. Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Satoh, F., Ito, S., Kimura, Y., Sasano, H. & Murakami, O. (2001) Role of urotensin II in patients on dialysis. Lancet, 358, 810-811.
31. Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S. & Murakami, O. (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci., 104, 1-5.
32. Tzanidis, A., Hannan, R.D., Thomas, W.G., Onan, D., Autelitano, D.J., See, F., Kelly, D.J., Gilbert, R.E. & Krum, H. (2003) Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res., 93, 246-253.
33. Zhu, Y.Z., Wang, Z.J., Zhu, Y.C., Zhang, L., Oakley, R.M., Chung, C.W., Lim, K.W., Lee, H.S., Ozoux, M.L., Linz, W., Böhm, M. & Kostenis, E. (2004) Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am. J. Physiol. Heart Circ. Physiol., 286, H830-H836.
34. Zou, Y., Nagai, R. & Yamazaki, T. (2001) Urotensin-II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett., 508, 57-60.